BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olson DE. Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry 2022;61:127-36. [PMID: 35060714 DOI: 10.1021/acs.biochem.1c00812] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 VanderZwaag J, Halvorson T, Dolhan K, Šimončičová E, Ben-Azu B, Tremblay MÈ. The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics. Neurochem Res 2023;48:1129-66. [PMID: 36327017 DOI: 10.1007/s11064-022-03772-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kargbo RB. Orally Active Forms of DMT, 5-MeO-DMT, and Long-Acting MDMA for the Treatment of Neuropsychiatric Disorders. ACS Med Chem Lett 2023. [DOI: 10.1021/acsmedchemlett.3c00077] [Reference Citation Analysis]
3 Lewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, Calkins MM, Bautista-Carro MA, Arsenault E, Telfer A, Taghavi-Abkuh FF, Malcolm NJ, El Sayegh F, Abizaid A, Schmid Y, Morton K, Halberstadt AL, Aguilar-Valles A, McCorvy JD. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep 2023;42:112203. [PMID: 36884348 DOI: 10.1016/j.celrep.2023.112203] [Reference Citation Analysis]
4 Lerer L, Reynolds E, Varia J, Blakolmer K, Lerer B. Incilius alvarius Cell-Based Synthesis of 5-Methoxy-N,N-Dimethyltryptamine. Psychedelic Medicine 2023;1:38-42. [DOI: 10.1089/psymed.2022.0001] [Reference Citation Analysis]
5 Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, Cameron LP, Patel SD, Hennessey JJ, Saeger HN, McCorvy JD, Gray JA, Tian L, Olson DE. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 2023;379:700-6. [PMID: 36795823 DOI: 10.1126/science.adf0435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, Chow WL, Gray JA, Olson DE. 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines. ACS Chem Neurosci 2023;14:351-8. [PMID: 36630260 DOI: 10.1021/acschemneuro.2c00718] [Reference Citation Analysis]
7 Kargbo RB. Psychedelic-Assisted Neuroplasticity for the Treatment of Mental Health Disorders. ACS Med Chem Lett 2023;14:133-5. [PMID: 36793424 DOI: 10.1021/acsmedchemlett.2c00546] [Reference Citation Analysis]
8 Alper K, Cange J, Sah R, Schreiber-Gregory D, Sershen H, Vinod KY. Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice. Front Pharmacol 2022;13:1074633. [PMID: 36686713 DOI: 10.3389/fphar.2022.1074633] [Reference Citation Analysis]
9 Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 2023;48:104-12. [PMID: 36123427 DOI: 10.1038/s41386-022-01389-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Lerer L, Varia J. A long trip into the universe: Psychedelics and space travel. Front Space Technol 2022;3. [DOI: 10.3389/frspt.2022.899159] [Reference Citation Analysis]
11 Kargbo RB. Restoration of Motor Function Post-Neurological Injury Using Serotonergic Agonist. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.2c00352] [Reference Citation Analysis]
12 Borgland SL, Neyens DM. Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies. J Psychiatry Neurosci 2022;47:E218-21. [PMID: 35705203 DOI: 10.1503/jpn.220090] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Kargbo RB. Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders. ACS Med Chem Lett 2022;13:888-90. [DOI: 10.1021/acsmedchemlett.2c00214] [Reference Citation Analysis]
14 Lerer L, Reynolds E, Varia J, Blakolmer K, Lerer B. Incilius alvarius cell-based synthesis of 5-MeO-DMT.. [DOI: 10.1101/2022.05.20.492789] [Reference Citation Analysis]
15 Kargbo RB. 5-HT Receptor Modulators for Therapeutic Use in the Treatment of Obsessive-Compulsive Disorder and Other Psychological Disorders. ACS Med Chem Lett 2022;13:770-2. [PMID: 35586441 DOI: 10.1021/acsmedchemlett.2c00153] [Reference Citation Analysis]
16 Kargbo RB. 3-Pyrrolidine-indole Derivatives as 5-HT2-Selective Receptor Modulators for the Potential Treatment of Mental Disorders. ACS Med Chem Lett 2022;13:749-51. [PMID: 35586424 DOI: 10.1021/acsmedchemlett.2c00128] [Reference Citation Analysis]
17 Kargbo RB. Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants. ACS Med Chem Lett 2022;13:537-9. [PMID: 35450349 DOI: 10.1021/acsmedchemlett.2c00129] [Reference Citation Analysis]